■ LEARNING WHAT SALICYLATES ARE
Medicines made from the bark of willow trees (genus Salix) and other salicylate-rich plants have been used as analgesics since at least 2000 bce. References exist on the Ebers Papyrus from Egypt (circa 1550 bce) as well as on ancient Sumerian tablets. 2 It was not until the 18th century, however, that Edmund Stone identifi ed salicin, a glycoside of salicylic acid and the active compound in willow bark extract. Searching for a way to reduce the burning throat and dyspepsia caused by salicylic acid, chemists at Friedrich Bayer & Company-the same group that popularized heroin as a "nonaddictive" form of morphine-eventually produced acetylsalicylic acid. Bayer gave the compound the brand name "Aspirin," using "A" for acetylation, "-spir-" for Spirea (another common source of salicylic acid), and "-in" as a conventional drug-name ending (Figure 1) . 3 
■ LEARNING (AND IGNORING) WHAT ASPIRIN CAN DO
In the 1940s, a general practitioner in California named Lawrence Craven recognized that many of his post-tonsillectomy patients had to be hospitalized for bleeding after he started recommending they use aspirin-containing chewing gum for pain relief. 4 Under the thendebated hypothesis that myocardial infarction (MI) involves thrombosis, he recommended that adult men should take aspirin daily. He believed that women had lower rates of MI because they were more likely to take aspirin, something that men did not view as a "masculine" thing to do.
In a series of letters in journals such as the Mississippi Valley Medical Journal, 5 Craven reported his observations of very low rates of MI and no strokes in aspirin users. Given the nonrigorous nature of his research and the obscure journals in which he published, his fi ndings languished for many years. Ironically, he died of an MI in 1957.
■ LEARNING HOW ASPIRIN WORKS (AND A FEW OTHER THINGS)
The history of aspirin research illustrates how the fi elds of hemostasis and infl ammation are now linked.
In the late 1960s, Weiss et al 6 reported that aspirin rapidly and irreversibly inhibits platelet aggregation. In parallel, using biological assays in work that eventually led to the Nobel Prize, Vane 7 discovered that infl ammation involves the de novo synthesis of prostaglandins and that aspirin directly inhibits this synthesis. Further work connecting these lines of investigation led us to understand that platelet aggregation is enhanced by the prostaglandin derivative thromboxane A2, produced by cyclooxygenase-1, and that aspirin irreversibly inhibits this enzyme by acetylation.
■ LEARNING WHEN TO USE ASPIRIN
After decades of research ranging from the Physicians' Health Study to well-named trials such as ARRIVE, ASCEND, and ASPREE, we now know that taking daily low doses of aspirin for primary prevention can reduce the risk of cardiovascular events and may reduce the risk of colorectal cancer-but at the cost of an increased risk of bleeding. 8 Which patients will gain the most benefi t and incur the least risk is still debated. What is certain, however, is that aspirin has an important role in acute coronary syndromes, secondary prevention of MI and stroke, and prevention of thrombosis after coronary stent placement. In the perioperative setting, we are learning that aspirin may benefi t patients with myocardial injury after noncardiac surgery, a recently described clinical entity associated with surprisingly high mortality rates.
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■ LEARNING WHEN NOT TO USE ASPIRIN
The perioperative period is a dangerous time-surgical stress, hypercoagulability, infl ammation, pain, and hemodynamic changes predispose to plaque rupture and supplydemand imbalance. It is therefore logical to hope aspirin would provide protection for atrisk patients in this context.
Unfortunately, results from the second Perioperative Ischemic Evaluation trial have dampened enthusiasm. 11 Aspirin has now joined clonidine and beta-blockers on the list of interventions that probably do not reduce perioperative cardiovascular mortality rates. Other than protecting against stent thrombosis, aspirin's main perioperative effect is to increase bleeding. Consequently, some surgical procedures mandate withdrawal of aspirin.
■ WHAT WE STILL NEED TO LEARN
Over the years, we have learned the broad outlines of using aspirin to prevent and treat cardiovascular disease, to relieve pain and infl ammation (its original purpose), and to prevent stent thrombosis.
However, many details remain to be fi lled in. We need to better defi ne groups who should and should not take aspirin for primary prevention. We also need to understand aspirin's role in cancer chemoprevention, to fi nd better ways to mitigate its undesirable effects, and to study its role in treating myocardial injury after noncardiac surgery.
Finally, we need to determine which (if any) patients without coronary stents will benefi t from continuing their aspirin perioperatively or even initiating aspirin therapy preoperatively.
Will humanity still be using salicylates 4,000 years from now? Probably not. But what we have learned and will continue to learn from this remarkable group of medications will certainly inform new and better therapies in the years to come. ■ Which patients will gain the most benefi t and incur the least risk is still debated
